Drug Trial Radar · NCT00289991
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
489
Actual
Start
Mar 2006
Primary completion
Feb 2009
Study completion Feb 2009
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study is to compare antifungal prophylaxis of Voriconazole and Itraconazole in subjects who have had a Stem Cell Transplant. The success of the end point will be measured using evidence of Infection, drug compliance and survival.
Conditions
- Antifungal Prophylaxis of Invasive Fungal Infections
Interventions
ItraconazoleDrug
Prophylaxis
Vfend - voriconazoleDrug
Prophylaxis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Success at Day 180: Percent of Responders (Randomization Strata)Time frame: Day 180 (Visit 9)
Locations
49 sites in 12 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Bmo, Czechia
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Cairo, Egypt
Pfizer Investigational Site
Caen, France
Pfizer Investigational Site
Créteil, France
Pfizer Investigational Site
Paris, France
Pfizer Investigational Site
Pessac, France
Pfizer Investigational Site
Rouen, France
Pfizer Investigational Site
Vandœuvre-lès-Nancy, France
Pfizer Investigational Site
Villejuif, France
Pfizer Investigational Site
Marseille, Cedex 09, France
Pfizer Investigational Site
Athens, Greece
Pfizer Investigational Site
Exohi Asvestohoriou, Thessaloniki, Greece
Pfizer Investigational Site
Amman, Jordan
Pfizer Investigational Site
Lisbon, Portugal
Pfizer Investigational Site
Porto, Portugal
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Saint Petersburg, Russia
Pfizer Investigational Site
Badalona, Barcelona, Spain
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Salamanca, Salamanca, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Ch-4031 Basel, Switzerland
Pfizer Investigational Site
Geneva, Switzerland
Pfizer Investigational Site
Ankara, Turkey (Türkiye)
Pfizer Investigational Site
Kayseri, Turkey (Türkiye)
Pfizer Investigational Site
Bristol, United Kingdom
Pfizer Investigational Site
Cambridge, United Kingdom
Pfizer Investigational Site
Cardiff, United Kingdom
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.